Share on StockTwits

CorMedix (NASDAQ:CRMD) CEO Randy Milby acquired 3,140 shares of CorMedix stock on the open market in a transaction that occurred on Friday, August 15th. The stock was purchased at an average cost of $1.99 per share, for a total transaction of $6,248.60. Following the completion of the purchase, the chief executive officer now directly owns 12,122 shares of the company’s stock, valued at approximately $24,123. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Zacks downgraded shares of CorMedix to a “neutral” rating in a research note on Monday, July 28th. They now have a $2.20 price target on the stock. Analysts at Roth Capital initiated coverage on shares of CorMedix in a research note on Thursday, July 24th. They set a “buy” rating and a $3.00 price target on the stock.

CorMedix (NASDAQ:CRMD) opened at 1.99 on Tuesday. CorMedix has a 52 week low of $0.66 and a 52 week high of $3.20. The stock has a 50-day moving average of $1.89 and a 200-day moving average of $1.98. The company’s market cap is $43.8 million.

CorMedix Inc (NASDAQ:CRMD) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.